Nakafri (Fluticasone Propionate)

Fluticasone Propionate, the active ingredient in Nakafri, is a corticosteroid presented as a nasal spray for nasal use. It treats allergic rhinitis, seasonal allergic rhinitis and nasal polyps in adults and children.

GNH USA supplies Nakafri as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nakafri, a nasal corticosteroid, acts on inflammatory processes of the nasal mucosa to relieve symptoms of allergic conditions. - Allergic rhinitis: reduces nasal congestion, sneezing, itching and rhinorrhea. - Seasonal allergic rhinitis: alleviates seasonal symptom flare‑ups and improves nasal airflow. - Nasal polyps: helps shrink polyps and improves breathing through the nose.

Common side effects are usually mild and limited to the site of administration.

Common Side Effects: - Nasal irritation or burning sensation. - Epistaxis (nosebleeds). - Headache. - Throat irritation or dryness. - Cough. - Altered taste or bitter taste.

Serious or Rare Side Effects: - Adrenal suppression with prolonged high‑dose use. - Cataracts or glaucoma. - Severe allergic reaction (anaphylaxis). - Fungal infection of the nasal mucosa. - Nasal septum perforation. - Systemic corticosteroid effects such as hyperglycemia.

Before using Nakafri, consider the following safety measures. - Assess for active nasal infection: avoid use if bacterial or fungal infection is present. - Hypersensitivity: discontinue if signs of allergic reaction occur. - Glaucoma or cataract history: monitor intra‑ocular pressure regularly. - Systemic corticosteroid exposure: use lowest effective dose to limit systemic absorption. - Concomitant intranasal steroids: avoid combining with other nasal corticosteroids. - Store at room temperature: keep in original container, protect from moisture and heat.

Fluticasone propionate may interact with other medicines that affect its metabolism or increase corticosteroid load.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) may raise systemic exposure. - Concurrent use of other intranasal corticosteroids increases risk of systemic effects.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin) may modestly increase levels. - Ritonavir or other protease inhibitors can elevate exposure. - Immunosuppressants (e.g., cyclosporine) may require monitoring for additive immunosuppression.